Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) was the recipient of a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 4,340,000 shares, a growth of 5.6% from the October 15th total of 4,110,000 shares. Based on an average daily volume of 524,700 shares, the days-to-cover ratio is currently 8.3 days. Currently, 7.9% of the company's stock are short sold.
In related news, CFO Cecilia Jones sold 2,542 shares of the stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total value of $124,634.26. Following the sale, the chief financial officer now owns 20,158 shares in the company, valued at approximately $988,346.74. This represents a 11.20 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 4.93% of the company's stock.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Acadian Asset Management LLC bought a new position in Agios Pharmaceuticals in the second quarter valued at approximately $37,000. Quest Partners LLC bought a new position in shares of Agios Pharmaceuticals in the 2nd quarter valued at $40,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Agios Pharmaceuticals by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company's stock valued at $94,000 after purchasing an additional 363 shares during the last quarter. CWM LLC raised its holdings in shares of Agios Pharmaceuticals by 554.7% during the 3rd quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company's stock worth $96,000 after buying an additional 1,836 shares in the last quarter. Finally, Quantbot Technologies LP bought a new stake in shares of Agios Pharmaceuticals during the 3rd quarter worth $146,000.
AGIO stock opened at $53.78 on Friday. The company has a market cap of $3.07 billion, a PE ratio of 4.73 and a beta of 0.75. Agios Pharmaceuticals has a 52 week low of $20.96 and a 52 week high of $62.58. The business has a 50-day simple moving average of $46.44 and a 200 day simple moving average of $43.87.
AGIO has been the subject of several research analyst reports. StockNews.com raised shares of Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, November 9th. Leerink Partnrs lowered Agios Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Friday, September 27th. Royal Bank of Canada reissued an "outperform" rating and set a $55.00 price target on shares of Agios Pharmaceuticals in a report on Friday, November 1st. Leerink Partners cut Agios Pharmaceuticals from an "outperform" rating to a "market perform" rating and lowered their price objective for the stock from $60.00 to $56.00 in a research report on Friday, September 27th. Finally, Scotiabank boosted their target price on shares of Agios Pharmaceuticals from $51.00 to $53.00 and gave the company a "sector outperform" rating in a research report on Friday, November 1st. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $52.33.
Get Our Latest Research Report on Agios Pharmaceuticals
Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Agios Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agios Pharmaceuticals wasn't on the list.
While Agios Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.